CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and sphere-forming capacity of the indicated tumor cells relative to monolayer cultures, demonstrates broad activity on lung CSCs, inhibiting mitochondrial respiratory activity, self-renewal and matrix invasion; inhibits tumor growth in in vivo models of NSCLC.
Reference:
[1]. Fernandez HR, et al. Cell Death Differ. 2018 Jul;25(7):1239-1258.